4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tumor Targeting via EPR: Strategies to Enhance Patient Responses

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The tumor accumulation of nanomedicines relies on the enhanced permeability and retention (EPR) effect. In the last 5-10 years, it has been increasingly recognized that there is a large inter- and intra-individual heterogeneity in EPR-mediated tumor targeting, explaining the heterogeneous outcomes of clinical trials in which nanomedicine formulations have been evaluated. To address this heterogeneity, as in other areas of oncology drug development, we have to move away from a one-size-fits-all tumor targeting approach, towards methods that can be employed to individualize and improve nanomedicine treatments. To this end, efforts have to be invested in better understanding the nature, the complexity and the heterogeneity of the EPR effect, and in establishing systems and strategies to enhance, combine, bypass and image EPR-based tumor targeting. In the present manuscript, we summarize key studies in which these strategies are explored, and we discuss how these approaches can be employed to enhance patient responses.

          Related collections

          Author and article information

          Journal
          8710523
          21484
          Adv Drug Deliv Rev
          Adv. Drug Deliv. Rev.
          Advanced drug delivery reviews
          0169-409X
          1872-8294
          5 September 2018
          19 July 2018
          May 2018
          10 September 2018
          : 130
          : 17-38
          Affiliations
          [1 ]Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, Germany
          [2 ]Department of Nuclear Medicine, RWTH Aachen University Clinic, Aachen, Germany
          [3 ]Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands
          [4 ]Department of Targeted Therapeutics, University of Twente, Enschede, The Netherlands
          Author notes
          [* ]Corresponding author ( tlammers@ 123456ukaachen.de )
          Article
          PMC6130746 PMC6130746 6130746 ems79418
          10.1016/j.addr.2018.07.007
          6130746
          30009886
          Categories
          Article

          Cancer, Nanomedicine, Drug delivery, Tumor targeting, EPR

          Comments

          Comment on this article